Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

A thousand new regulators

Executive Summary

FDA will add 1,163 new employees to its staff by the end of the fiscal year, according to the agency. One thousand and five already are on board and 158 are due to report by Sept. 28. Another 160 candidates have accepted offers but are still undergoing clearance and related security processes, FDA says. The new hires, the result of a staffing initiative launched in the spring, will increase agency personnel to authorized levels (1"The Pink Sheet," May 5, 2008, p. 7). More than 850 of the new staff are in scientific or medical professions

You may also be interested in...



CDER, ORA To Be Major Beneficiaries Of Speedier FDA Hiring Process

As Congress debates increased funding and other steps to improve FDA oversight of imported drugs, the agency plans to hire 1,317 people in the next six months to bring staff numbers up to their full authorized levels

Progress Of Bayer’s Postmarket Essure Study ‘Inadequate’ Says FDA

The US FDA labelled the progress of Bayer’s 522 postmarket study of its Essure birth control device, which was pulled off the market in 2018, as “inadequate” due to significant numbers of women dropping out.

Lilly Looks To Accelerate Tirzepatide Into Obesity With Rolling Submission

Plan for rolling submission means US FDA filing of GIP/GLP1 agonist in obesity could be complete by April 2023, setting up possibility of late 2023 approval.

Latest News
See All
UsernamePublicRestriction

Register

PS050084

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel